Journal of Biological Chemistry APC and Open Access: Current JBC Pricing, Member Discount, and What Authors Really Pay

Those numbers matter because JBC is not a prestige-purchase journal. It is a community biochemistry journal with unusually fast editorial handling and unusually long citation life. If the paper belongs there, the APC is moderate by current life-science standards.

The current figure is down from 4.0 in 2023 to 3.9 in 2024, so nobody should treat JBC as a citation-maximizing venue. But that is not why authors choose it. JBC still carries deep recognition in biochemistry, a very large editorial board, and a mechanism-first scope that is broader than many specialty journals.

For JBC, the APC question is simpler than it is at hybrid journals.

• There is no free subscription path.
• The journal is already fully open access.
• The real cost question is whether you can qualify for the member-discounted schedule and whether your grant or institution will cover the bill cleanly.

That makes JBC different from Cell Press hybrid titles where the first decision is whether you need OA at all. At JBC, the paper will publish open access either way. The practical choice is about member status, funding path, and fit.

Three official details matter here.

1. The current ASBMB JBC flyer quotes $2,300 for members and $2,800 for nonmembers.
2. The JBC guide for authors states that member and nonmember APCs are detailed on the open-access information page and that the corresponding author entered in Editorial Manager must be the ASBMB member to receive the discount.
3. ScienceDirect still shows a generic USD 3,430 listing, which means authors should not assume every public JBC pricing surface is synchronized perfectly.

The right operational move is:

• decide who the corresponding author will be before submission
• confirm whether that person is an active ASBMB member
• verify the exact price shown inside the submission and payment workflow

That is better than planning around one public page and discovering late that the member-discount rule was not satisfied.

In pre-submission review work, JBC submissions usually go wrong in one of three ways.

The paper is biological, but not biochemical enough. JBC explicitly emphasizes novel and important mechanistic insights. If the strongest claim is a phenotype or pathway association without biochemical mechanism, the APC is the wrong question.

The authors underestimate the member-discount rule. We see papers where the lab assumes "someone in the group is an ASBMB member" is enough. The guide for authors is narrower than that: the corresponding author in the system has to be the member.

The manuscript is trying to use JBC as a fallback for work that belongs in a narrower specialty title. JBC is broad, but broad does not mean unfocused. Papers still need a clear mechanistic biochemical contribution.

For 2026, the honest answer is:

• JBC is fully open access
• the journal-specific member and nonmember pricing looks materially lower than the generic ScienceDirect listing
• the corresponding-author membership rule matters
• fit matters more than the invoice

If you are the corresponding author and can use the ASBMB member rate, JBC is one of the more economical serious biochemistry venues in this part of the market. If you are not using the member discount, verify the final amount early so the submission plan does not drift into avoidable confusion.

Before you submit, a Journal of Biological Chemistry submission readiness check can pressure-test whether the paper actually clears JBC's mechanism-first editorial bar.